Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
- Written by PR Newswire
--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients receiving 12-week treatment of ASC41 tablet
--At Week 12, up to 93.3% patients achieved at least a 30% relative reduction in liver fat contentfrom baseline
--At Week 12, placebo-adjusted mean relative reductions...














